CAPR — Capricor Therapeutics, Inc.

Summary of Capricor Therapeutics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, Capricor reported cash and marketable securities totaling approximately $318 million, up from $151.5 million in 2024, bolstered by a public offering that generated net proceeds of $162 million.
• Revenue: The company reported no revenue for 2025, a decline from $11.1 million in 2024, primarily due to the completion of revenue recognition from a previous distribution agreement.
• Operating Expenses: Total operating expenses for 2025 were approximately $29.2 million, up from $18.8 million in 2024. Full-year operating expenses reached about $108.1 million, compared to $64.8 million in 2024.
• Net Loss: The net loss for 2025 was approximately $30.2 million, compared to $7.1 million in 2024, with a full-year net loss of about $105 million versus $40.5 million in 2024.

2. Strategic Updates and Business Highlights

• Regulatory Milestone: The FDA accepted Capricor's response to a complete response letter (CRL) regarding its biologics license application (BLA) for deramycin, with a target action date set for August 22, 2026.
• HOPE-3 Trial Results: The pivotal Phase 3 HOPE-3 trial demonstrated significant efficacy in treating Duchenne muscular dystrophy (DMD) cardiomyopathy, achieving primary and secondary endpoints, including a 91% slowing of disease progression in left ventricular ejection fraction.
• Manufacturing Readiness: Capricor's GMP facility in San Diego is operational and ready to support an initial commercial launch, with plans for expansion to increase capacity from 250 to approximately 2,500 patients annually by late 2027.
• Pipeline Expansion: The company is exploring potential applications of deramycin for Becker dystrophy and advancing its exosome platform for various therapeutic programs.

3. Forward Guidance and Outlook

• Commercial Launch Preparation: Capricor is focused on building a commercial infrastructure to support the potential launch of deramycin, including hiring for patient support and market access roles.
• Financial Position: The company believes its current cash reserves are sufficient to fund operations into 2027, excluding potential product revenues and the monetization of a priority review voucher.
• Clinical Development: Capricor is preparing for additional clinical studies and regulatory discussions, particularly regarding the labeling of deramycin for both skeletal and cardiac manifestations of DMD.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The absence of revenue in 2025 raises concerns about the company's financial sustainability until product approval and market entry.
• Increased Operating Losses: The substantial increase in net losses indicates heightened operational costs as the company invests in clinical trials and infrastructure without immediate revenue generation.
• Regulatory Uncertainties: While the FDA has not identified any review issues, the potential for additional questions during the resubmission process remains a risk.
• Market Competition: The landscape for DMD treatments is competitive, and Capricor must ensure its product differentiation and market readiness to capture patient interest.

5. Notable Q&A Insights

• Advisory Committee (AdCom) Expectations: Management indicated uncertainty regarding the likelihood of an AdCom meeting, noting that the FDA has not scheduled one recently.
• Labeling Discussions: There is anticipation for discussions around the labeling of deramycin, with hopes for inclusion of both cardiomyopathy and skeletal muscle indications based on strong clinical data.
• Patient Transition: Capricor plans to transition clinical trial patients to commercial drug post-launch, with a focus on ensuring access for all eligible patients.
• Manufacturing Expansion: The company is actively planning for additional manufacturing capacity to meet anticipated demand, contingent on successful BLA approval.

Overall, Capricor Therapeutics is positioned at a critical juncture with significant regulatory milestones and a strong financial position, but it faces challenges related to revenue generation and operational losses as it prepares for the potential launch of deramycin.